Calcium chloride: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 5: Line 5:
|indicationType=treatment
|indicationType=treatment
|indication=[[hypocalcemia]], lead colic, magnesium intoxication, [[hyperkalemia]], cardiac resuscitation
|indication=[[hypocalcemia]], lead colic, magnesium intoxication, [[hyperkalemia]], cardiac resuscitation
|adverseReactions=[[tingling sensation]]s, calcium taste, a sense of oppression or “heat wave, [[peripheral vasodilation]], local “burning” sensation, moderate fall in blood pressure
|adverseReactions=[[tingling sensation]]s, calcium taste, a sense of oppression or “heat wave, peripheral vasodilation, local “burning” sensation, [[hypotention]]
|blackBoxWarningTitle=Warning Title
|blackBoxWarningTitle=Warning Title
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
Line 12: Line 12:
Calcium Chloride Injection, USP, 10% is indicated:
Calcium Chloride Injection, USP, 10% is indicated:


* In the treatment of [[hypocalcemia]] in conditions requiring a prompt increase in plasma calcium levels (e.g., neonatal tetany and tetany due to parathyroid deficiency, vitamin D deficiency and alkalosis) and for prevention of [[hypocalcemia]] during exchange transfusions.
* In the treatment of [[hypocalcemia]] in conditions requiring a prompt increase in plasma calcium levels (e.g., neonatal tetany and tetany due to parathyroid deficiency, vitamin D deficiency and [[alkalosis]]) and for prevention of [[hypocalcemia]] during exchange transfusions.


* As adjunctive therapy in the management of acute symptoms in lead colic.
* As adjunctive therapy in the management of acute symptoms in lead colic.
Line 54: Line 54:
'''INTRAVENOUS USE'''
'''INTRAVENOUS USE'''


'''''Hypocalcemic Disorders'''''
''''Hypocalcemic Disorders''''
*  0.2 mL /kg of body weight. Maximum 1-10 mL/day.
*  0.2 mL /kg of body weight. Maximum 1-10 mL/day.
   
|offLabelPedGuideSupport===Indications and Dosing==
|offLabelPedGuideSupport===Indications and Dosing==


Line 81: Line 77:


* The usual precautions for intravenous therapy should be observed. If time permits, the solution should be warmed to body temperature. The injection should be halted if the patient complains of any discomfort; it may be resumed when symptoms disappear. Following injection, the patient should remain recumbent for a short time.
* The usual precautions for intravenous therapy should be observed. If time permits, the solution should be warmed to body temperature. The injection should be halted if the patient complains of any discomfort; it may be resumed when symptoms disappear. Following injection, the patient should remain recumbent for a short time.
   
|drugBox={{chembox2
|drugBox={{Drugbox2
| Verifiedfields = changed
| verifiedrevid =  
| Watchedfields = changed
| IUPAC_name =  
| verifiedrevid = 477163394
| image =  
| Name = Calcium chloride
| drug_name =  
| ImageFile = File:Kristallstruktur Calciumchlorid.png
 
| ImageSize = 160px
<!--Clinical data-->
| ImageName = Structure of calcium chloride, (chlorine is green, calcium is gray)
| tradename =  
| ImageFile1 = Calcium chloride CaCl2.jpg
| MedlinePlus =  
| ImageSize1 = 200px
| licence_US =  
| ImageName1 = Sample of calcium chloride
| pregnancy_AU =  
| IUPACName = Calcium chloride
| pregnancy_US =  
| OtherNames = Calcium(II) chloride, Calcium dichloride, E509
| legal_status =  
| Section1 = {{Chembox Identifiers
| routes_of_administration =
| ChemSpiderID = 23237
 
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
<!--Pharmacokinetic data-->
| UNII = OFM21057LP
| bioavailability =  
| UNII_Ref = {{fdacite|correct|FDA}}
| metabolism =  
| ChEMBL = 1200668
| elimination_half-life =  
| ChEMBL_Ref = {{ebicite}}
| excretion =  
| ChEBI = 3312
 
| ChEBI_Ref = {{ebicite}}
<!--Identifiers-->
| DrugBank = DB01164
| CAS_number_Ref =  
| DrugBank_Ref = {{drugbankcite}}
| CAS_number =  
| SMILES = [Ca+2].[Cl-].[Cl-]
| ATC_prefix =  
| InChI = 1/Ca.2ClH/h;2*1H/q+2;;/p-2
| ATC_suffix =  
| InChIKey = UXVMQQNJUSDDNG-NUQVWONBAG
| PubChem =  
| StdInChI = 1S/Ca.2ClH/h;2*1H/q+2;;/p-2
| IUPHAR_ligand =  
| StdInChI_Ref = {{stdinchicite}}
| DrugBank_Ref =  
| StdInChIKey = UXVMQQNJUSDDNG-UHFFFAOYSA-L
| DrugBank =  
| StdInChIKey_Ref = {{stdinchicite}}
| ChemSpiderID_Ref =  
| CASNo = 10043-52-4
| ChemSpiderID =  
| CASNo_Ref = {{cascite}}
| UNII_Ref =  
| CASNo_Comment =
| UNII =  
| CASNo1 = 22691-02-7
| KEGG_Ref =  
| CASNo1_Ref = {{cascite}}
| KEGG =  
| CASNo1_Comment = (monohydrate)
| ChEBI_Ref =  
| CASNo2 = 10035-04-8
| ChEBI =  
| CASNo2_Ref = {{cascite}}
| ChEMBL_Ref =  
| CASNo2_Comment = (dihydrate)
| ChEMBL =  
| CASNo3 = 25094-02-4
 
| CASNo3_Ref = {{cascite}}
<!--Chemical data-->
| CASNo3_Comment = (tetrahydrate)
| C= | H= | N= | O=  
| CASNo4 = 7774-34-7
| molecular_weight =  
| CASNo4_Ref = {{cascite}}
| smiles =  
| CASNo4_Comment = (hexahydrate)
| InChI =  
| PubChem = 24854
| InChIKey =  
| PubChem_Ref = {{pubchemcite}}
| StdInChI_Ref =  
| RTECS = EV9800000
| StdInChI =  
| EC-number = 233-140-8
| StdInChIKey_Ref =  
| ATCCode_prefix = A12
| StdInChIKey =  
| ATCCode_suffix = AA07
| melting_point =  
| ATC_Supplemental = {{ATC|B05|XA07}}, {{ATC|G04|BA03}}
  }}
| Section2 = {{Chembox Properties
| Ca=1|Cl=2
| Appearance = White powder, [[hygroscopic]]
| Odor = Odorless
| Density = 2.15 g/cm<sup>3</sup> (anhydrous)<br> 2.24 g/cm<sup>3</sup> (monohydrate)<br> 1.85 g/cm<sup>3</sup> (dihydrate)<br> 1.83 g/cm<sup>3</sup> (tetrahydrate)<br> 1.71 g/cm<sup>3</sup> (hexahydrate)<ref name=crc>{{CRC90}}</ref>
| MeltingPtC = 772-775
| Melting_notes = <br> anhydrous<ref name=pphoic /><br> {{convert|260|C|F K}}<br> monohydrate, decomposes<br> {{convert|175|C|F K}}<br> dihydrate, decomposes<br> {{convert|45.5|C|F K}}<br> tetrahydrate, decomposes<ref name=pphoic>{{cite book|last = Pradyot|first = Patnaik|year = 2003|title = Handbook of Inorganic Chemicals|publisher = The McGraw-Hill Companies, Inc.|isbn = 0-07-049439-8|page = 162}}</ref><br> {{convert|30|C|F K}}<br> hexahydrate, decomposes<ref name=crc />
| BoilingPtC = 1935
| Boiling_notes = <br> anhydrous<ref name=crc />
| Solubility = Hexahydrate:<br> 49.4 g/100 mL (−25 °C)<br> 59.5 g/100 mL (0 °C)<br> 65 g/100 mL (10 °C)<br> 81.1 g/100 mL (25 °C)<ref name=crc /><br> 102.2 g/100 mL (30.2 °C)<br> α-Tetrahydrate:<br> 90.8 g/100 mL (20 °C)<br> 114.4 g/100 mL (40 °C)<br> Dihydrate:<br> 134.5 g/100 mL (60 °C)<br> 152.4 g/100 mL (100 °C)<ref name=sioc>{{cite book|last = Seidell|first = Atherton|last2 = Linke|first2 = William F.|year = 1919|title = Solubilities of Inorganic and Organic Compounds|publisher = D. Van Nostrand Company|place = New York|edition = 2nd|page = 196}}</ref>
| SolubleOther = Soluble in [[acetic acid|CH<sub>3</sub>COOH]], [[alcohol]]s<br> Insoluble in liquid [[ammonia|NH<sub>3</sub>]], [[dimethyl sulfoxide|DMSO]], [[ethyl acetate|CH<sub>3</sub>COOC<sub>2</sub>H<sub>5</sub>]]<ref name=chemister />
| Solubility1 = 18.3 g/100 g (0 °C)<br> 25.8 g/100 g (20 °C)<br> 35.3 g/100 g (40 °C)<br> 56.2 g/100 g (70 °C)<ref name=chemister>{{cite web|last = Anatolievich|first = Kiper Ruslan|website = http://chemister.ru|url = http://chemister.ru/Database/properties-en.php?dbid=1&id=558|title = cadmium chloride|accessdate = 2014-07-07}}</ref>
| Solvent1 = ethanol
| Solubility2 = 21.8 g/100 g (0 °C)<br> 29.2 g/100 g (20 °C)<br> 38.5 g/100 g (40 °C)<ref name=chemister />
| Solvent2 = methanol
| Solubility3 = 0.1 g/kg (20 °C)<ref name=chemister />
| Solvent3 = acetone
| Solubility4 = 16.6 g/kg<ref name=chemister />
| Solvent4 = pyridine
| Viscosity = 3.34 cP (787 °C)<br> 1.44 cP (967 °C)<ref name=chemister />
| MagSus = −5.47·10<sup>−5</sup> cm<sup>3</sup>/mol<ref name=crc />
| pKa = 8–9 (anhydrous)<br> 6.5–8.0 (hexahydrate)
| RefractIndex = 1.52
  }}
| Section3 = {{Chembox Structure
| Coordination = [[Octahedral]] (Ca<sup>2+</sup>, anhydrous)
| CrystalStruct = [[orthorhombic crystal system|Orthorhombic]] ([[rutile]], anhydrous), [[Pearson symbol|oP6]]<br> [[tetragonal crystal system|Tetragonal]] (anhydrous, > 217&nbsp;°C), [[Pearson symbol|oP6]]<ref name=isc>{{cite book|title = Inorganic Structural Chemistry|first = Ulrich|last = Müller|edition = 2nd|url = http://books.google.com/books?id=s3KlfXCY11sC&pg=PA33|website = http://www.wiley.com|year = 2006|publisher = John Wiley & Sons Ltd.|place = England|isbn = 978-0-470-01864-4|page = 33}}</ref><br> [[trigonal crystal system|Trigonal]] (hexahydrate)
| SpaceGroup = Pnnm, No. 58 (anhydrous)<br> P4<sub>2</sub>/mnm, No. 136 (anhydrous, > 217&nbsp;°C)<ref name=isc />
| PointGroup = 2/m 2/m 2/m (anhydrous)<br> 4/m 2/m 2/m (anhydrous, > 217&nbsp;°C)<ref name=isc />
| LattConst_a = 6.259&nbsp;Å
| LattConst_b = 6.444&nbsp;Å
| LattConst_c = 4.17&nbsp;Å (anhydrous, 17&nbsp;°C)<ref name=isc />
| LattConst_alpha = 90
  }}
| Section4 = {{Chembox Thermochemistry
| HeatCapacity = 72.89 J/mol·K (anhydrous)<ref name=crc /><br> 106.23 J/mol·K (monohydrate)<br> 172.92 J/mol·K (dihydrate)<br> 251.17 J/mol·K (tetrahydrate)<br> 300.7 J/mol·K (hexahydrate)<ref name=pphoic />
| Entropy = 108.4 J/mol·K<ref name=crc /><ref name=pphoic />
| DeltaHf = −795.42 kJ/mol (anhydrous)<ref name=crc /><br> −1110.98 kJ/mol (monohydrate)<br> −1403.98 kJ/mol (dihydrate)<br> −2009.99 kJ/mol (tetrahydrate)<br> − 2608.01 kJ/mol (hexahydrate)<ref name=pphoic />
| DeltaGf = −748.81 kJ/mol<ref name=crc /><ref name=pphoic />
| DeltaHc =
  }}
| Section7 = {{Chembox Hazards
| GHSPictograms = {{GHS07}}<ref name="sigma">{{Sigma-Aldrich|id=499609|name=Calcium chloride|accessdate=2014-07-07}}</ref>
| GHSSignalWord = Warning
| HPhrases = {{H-phrases|319}}<ref name="sigma" />
| PPhrases = {{P-phrases|305+351+338}}<ref name="sigma" />
| EUClass = {{Hazchem Xi}}
| EUIndex = 017-013-00-2
| RPhrases = {{R36}}
| SPhrases = {{S22}}, {{S24}}
| NFPA-H = 2
| NFPA-F = 0
| NFPA-R = 1
| NFPA_Ref = <ref name=fca>{{cite web|title = MSDS of Calcium chloride|url = https://www.fishersci.ca/viewmsds.do?catNo=C6143|website = https://www.fishersci.ca|publisher = Fisher Scientific|accessdate = 2014-07-07}}</ref>
| LD50 = 1000 mg/kg (rats, oral)<ref name=fca />
  }}
| Section8 = {{Chembox Related
| OtherAnions = [[Calcium fluoride]]<br> [[Calcium bromide]]<br> [[Calcium iodide]]
| OtherCations = [[Beryllium chloride]]<br> [[Magnesium chloride]]<br> [[Strontium chloride]]<br> [[Barium chloride]]<br> [[Radium chloride]]
}}
}}
}}
|mechAction=(Description)
|structure=Calcium Chloride Injection, USP, 10%, is a sterile aqueous solution containing, in each mL, 100 mg (1.36 mEq) calcium chloride. The pH of the solution may have been adjusted with hydrochloric acid and / or calcium hydroxide, when necessary. The air above the liquid in the individual containers has been displaced by flushing with nitrogen during the filling operation. The preparation contains no antimicrobial preservatives and is intended as a single-dose vial; once the unit is assembled and used, any remaining portion of the solution must be discarded with the entire unit.
|structure=Calcium Chloride Injection, USP, 10%, is a sterile aqueous solution containing, in each mL, 100 mg (1.36 mEq) calcium chloride. The pH of the solution may have been adjusted with hydrochloric acid and / or calcium hydroxide, when necessary. The air above the liquid in the individual containers has been displaced by flushing with nitrogen during the filling operation. The preparation contains no antimicrobial preservatives and is intended as a single-dose vial; once the unit is assembled and used, any remaining portion of the solution must be discarded with the entire unit.
Calcium Chloride, USP, contains two molecules of water of hydration and is chemically designated as CaCl2 • 2H20.
Calcium Chloride, USP, contains two molecules of water of hydration and is chemically designated as CaCl2 • 2H20.

Revision as of 15:42, 19 December 2014

Calcium chloride
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Calcium chloride is a {{{drugClass}}} that is FDA approved for the treatment of hypocalcemia, lead colic, magnesium intoxication, hyperkalemia, cardiac resuscitation. Common adverse reactions include tingling sensations, calcium taste, a sense of oppression or “heat wave, peripheral vasodilation, local “burning” sensation, hypotention.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

Calcium Chloride Injection, USP, 10% is indicated:

  • In the treatment of hypocalcemia in conditions requiring a prompt increase in plasma calcium levels (e.g., neonatal tetany and tetany due to parathyroid deficiency, vitamin D deficiency and alkalosis) and for prevention of hypocalcemia during exchange transfusions.
  • As adjunctive therapy in the management of acute symptoms in lead colic.
  • In the treatment of magnesium intoxication due to overdosage of magnesium sulfate.
  • In severe hyperkalemia, to combat deleterious effects on electrocardiographic (ECG) function, pending correction of the potassium level in the extracellular fluid.
  • In cardiac resuscitation, particularly after open heart surgery, when epinephrine fails to improve weak or ineffective myocardial contractions.

Dosing

INTRACARDIAC USE

  • For cardiac resuscitation, inject into the ventricular cavity, not into the heart muscle.
  • Usual Adult Dosage: 200 to 800 mg (2 to 8 mL) when injected into the ventricular cavity.

INTRAVENOUS USE

Hypocalcemic Disorders

  • Usual Adult Dosage: 500 mg to 1 g (5 to 10 mL) at intervals of 1 to 3 days, depending on the response of the patient and / or results of serum calcium determinations. Repeated injections may be required because of rapid excretion of calcium.

Magnesium Intoxication

  • Initial Adult Dose: 500 mg (5 mL) administered promptly and the patient observed for signs of recovery before further doses are given.

Hyperkalemic ECG Disturbances of Cardiac Function

  • Dosage should be adjusted by constant monitoring of ECG changes during administration.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Indications and Dosing

  • Contains 100 mg calcium chloride per mL; 27.3 mg or 1.36 mEq of elemental calcium per mL
  • Hypocalcemia: 200 mg to 1 g calcium chloride (2 to 10 mL of a 10% solution; 55 to 273 mg elemental calcium) IV every 1 to 3 days; MAX rate, 1 mL/min

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Calcium chloride in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Indications

INTRACARDIAC USE

  • 0.2 mL/kg of body weight.

INTRAVENOUS USE

'Hypocalcemic Disorders'

  • 0.2 mL /kg of body weight. Maximum 1-10 mL/day.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Indications and Dosing

  • Contains 100 mg calcium chloride per mL; 27.3 mg or 1.36 mEq of elemental calcium per mL.
  • Advanced cardiac life support: 20 mg/kg calcium chloride (0.2 mL/kg of 10% solution; 5.5 mg/kg elemental calcium) IV or INTRAOSSEOUS; administer slowly; MAX dose 2 g calcium chloride (546 mg elemental calcium).
  • Hypocalcemia: 2.7 to 5 mg/kg calcium chloride (0.027 to 0.05 mL/kg of a 10% solution; 0.74 to 1.37 mg/kg elemental calcium) IV every 4 to 6 hours; MAX rate, 1 mL/min.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Calcium chloride in pediatric patients.

Contraindications

Warnings

  • Calcium chloride should be injected into a large vein very slowly, as it may cause peripheral vasodilatation and a cutaneous burning sensation. A moderate fall in blood pressure due to vasodilatation may attend the injection. Since calcium chloride is an acidifying salt, it is usually undesirable in the treatment of hypocalcemia or renal insufficiency.

Adverse Reactions

Clinical Trials Experience

  • Rapid I.V. injection may cause the patient to complain of tingling sensations, a calcium taste, a sense of oppression or “heat wave.”
  • Injections of calcium chloride are accompanied by peripheral vasodilation as well as a local “burning” sensation, and there may be a moderate fall in blood pressure.

Postmarketing Experience

There is limited information regarding Calcium chloride Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Calcium chloride Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Calcium chloride in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Calcium chloride in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Calcium chloride during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Calcium chloride in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Calcium chloride in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Calcium chloride in geriatric settings.

Gender

There is no FDA guidance on the use of Calcium chloride with respect to specific gender populations.

Race

There is no FDA guidance on the use of Calcium chloride with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Calcium chloride in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Calcium chloride in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Calcium chloride in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Calcium chloride in patients who are immunocompromised.

Others

Administration and Monitoring

Administration

Intravenous

INJECT SLOWLY

  • Calcium Chloride Injection, USP, 10%, is administered only by slow intravenous injection (not to exceed 1 mL/min) and / or in cardiac resuscitation, by injection into the ventricular cavity. It must not be injected into the myocardium.
  • The usual precautions for intravenous therapy should be observed. If time permits, the solution should be warmed to body temperature. The injection should be halted if the patient complains of any discomfort; it may be resumed when symptoms disappear. Following injection, the patient should remain recumbent for a short time.

Monitoring

There is limited information regarding Calcium chloride Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Calcium chloride and IV administrations.

Overdosage

There is limited information regarding Calcium chloride overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

Template:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox E numberTemplate:Chembox RTECSTemplate:Chembox AppearanceTemplate:Chembox OdourTemplate:Chembox DensityTemplate:Chembox MeltingPtTemplate:Chembox BoilingPtTemplate:Chembox SolubilityInWaterTemplate:Chembox SolubilityTemplate:Chembox SolubilityTemplate:Chembox SolubilityTemplate:Chembox SolubilityTemplate:Chembox SolubilityTemplate:Chembox pKaTemplate:Chembox MagSusTemplate:Chembox RefractIndexTemplate:Chembox ViscosityTemplate:Chembox StructureTemplate:Chembox ThermochemistryTemplate:Chembox GHSPictogramsTemplate:Chembox GHSSignalWordTemplate:Chembox HPhrasesTemplate:Chembox PPhrasesTemplate:Chembox NFPATemplate:Chembox Lethal amounts (set)Template:Chembox OtherAnionsTemplate:Chembox OtherCationsTemplate:Chembox Supplement
Template:Chembox header2 | Calcium chloride
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
DrugBank
ECHA InfoCard Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).
UNII
Properties
CaCl2
Molar mass 110.98 g·mol−1
Hazards
Related compounds
Template:Chembox header2 | Except where noted otherwise, data are given for
materials in their standard state
(at 25 °C, 100 kPa)
Infobox disclaimer and references

Mechanism of Action

There is limited information regarding Calcium chloride Mechanism of Action in the drug label.

Structure

Calcium Chloride Injection, USP, 10%, is a sterile aqueous solution containing, in each mL, 100 mg (1.36 mEq) calcium chloride. The pH of the solution may have been adjusted with hydrochloric acid and / or calcium hydroxide, when necessary. The air above the liquid in the individual containers has been displaced by flushing with nitrogen during the filling operation. The preparation contains no antimicrobial preservatives and is intended as a single-dose vial; once the unit is assembled and used, any remaining portion of the solution must be discarded with the entire unit. Calcium Chloride, USP, contains two molecules of water of hydration and is chemically designated as CaCl2 • 2H20.

Pharmacodynamics

(Description)

Pharmacokinetics

(Description)

Nonclinical Toxicology

(Description)

Clinical Studies

There is limited information regarding Calcium chloride Clinical Studies in the drug label.

How Supplied

CALCIUM CHLORIDE INJECTION, USP, 10%

In unit-use packages containing a Luer-Jet™ Luer-Lock Prefilled Syringe. Stock No. 3304 NDC 76329-3304-1 10 mL Ten cartons per package.

Syringe Assembly Directions:

USE ASEPTIC TECHNIQUE

Do not assemble until ready to use.

This image is provided by the National Library of Medicine.

Storage

  • Store at controlled room temperature 15° to 30°C (59° to 86°F).

Images

Drug Images

{{#ask: Page Name::Calcium chloride |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Calcium chloride |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Calcium chloride Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Calcium chloride interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

CALCIUM CHLORIDE

Look-Alike Drug Names

There is limited information regarding Calcium chloride Look-Alike Drug Names in the drug label.

Drug Shortage Status

Drug Shortage

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ 1.0 1.1 1.2 1.3 1.4 Template:CRC90
  2. ↑ Seidell, Atherton; Linke, William F. (1919). Solubilities of Inorganic and Organic Compounds (2nd ed.). New York: D. Van Nostrand Company. p. 196.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 Anatolievich, Kiper Ruslan. "cadmium chloride". http://chemister.ru. Retrieved 2014-07-07. External link in |website= (help)
  4. ↑ 4.0 4.1 Pradyot, Patnaik (2003). Handbook of Inorganic Chemicals. The McGraw-Hill Companies, Inc. p. 162. ISBN 0-07-049439-8.
  5. ↑ 5.0 5.1 5.2 Template:Sigma-Aldrich
  6. ↑ 6.0 6.1 "MSDS of Calcium chloride". https://www.fishersci.ca. Fisher Scientific. Retrieved 2014-07-07. External link in |website= (help)

{{#subobject: 

 |Label Page=Calcium chloride
 |Label Name=Calcium chloride ingredients and appearance.png

}}

{{#subobject: 

 |Label Page=Calcium chloride
 |Label Name=Calcium chloride fig02.jpg

}}

{{#subobject: 

 |Label Page=Calcium chloride
 |Label Name=Calcium chloride fig01.jpg

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Calcium_chloride&oldid=1049405"